Business Context and Reporting Period
This Form 8-K, filed on April 3, 2025, reports events occurring on March 28, 2025, for Tivic Health Systems, Inc. (TIVC). The filing details the exercise of an exclusive option to expand a license agreement with Statera Biopharma, Inc. regarding the TLR5 agonist program known as Entolimod. While the request metadata references "Valion Bio, Inc.", the filing text explicitly identifies the registrant as Tivic Health Systems, Inc.
Key Financial Metrics and Transaction Details
- Transaction Type: Exercise of an exclusive option and acceleration of a milestone payment.
- Milestone Payment Accelerated: $500,000 (originally due upon filing an IND and initiating a Phase 2 clinical study for Neutropenia).
- Payment Consideration: Issuance of unregistered securities consisting of 55,704 shares of common stock and 131.1267 shares of Series A Non-Voting Convertible Preferred Stock.
- Recipients: Statera Biopharma, Inc. and Avenue Venture Opportunities Fund, L.P.
- Future Obligations: The company remains liable for subsequent milestone payments of $750,000 (Phase III completion) and $1,500,000 (FDA approval) for the Neutropenia indication.
- Liquidity and Cash Flow: The filing does not provide current cash balances, total debt, or liquidity metrics. The transaction was executed via stock issuance rather than cash outflow.
Material Changes Versus Prior Period
The primary material change is the expansion of the company's licensed portfolio to include the Neutropenia indication for Entolimod. Additionally, the company accelerated a $500,000 milestone payment obligation, converting a future liability into an immediate equity issuance. This contrasts with the prior period where the option was held but not exercised, and the milestone payment was contingent on future clinical study initiation.
Guidance, Outlook, and Risks
- Management Commentary: The company is obligated to develop and commercialize the Neutropenia indication at its own cost and expense.
- Risks and Contingencies: Future financial obligations are contingent upon achieving specific clinical and regulatory milestones (Phase III completion and FDA approval). Failure to meet these milestones would eliminate the associated payment obligations.
- Unusual Items: The acceleration of the milestone payment prior to the actual filing of the IND and initiation of the Phase 2 study is a discretionary action by the company.
- Securities Restrictions: The issued shares are "restricted securities" and cannot be sold in the U.S. absent registration or an exemption.
Investor Verification Checklist
- Verify the exact number of shares issued (55,704 common and 131.1267 Series A Preferred) and their impact on total share count and dilution.
- Confirm the valuation methodology used to determine the stock consideration for the $500,000 milestone payment.
- Review the full text of the License Agreement (Exhibit 10.1 to the Prior 8-K) for detailed royalty terms and adjustment clauses.
- Assess the company's current cash position to determine its ability to fund the required development costs for the Neutropenia indication.
- Clarify the discrepancy between the request metadata ("Valion Bio, Inc.") and the filing registrant ("Tivic Health Systems, Inc.").